Kiniksa transitions from survival risk to growth, targeting dominance in the pericarditis market with robust cash flow and expanding margins. KNSA's Arcalyst drives revenue growth, with 2026 guidance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results